Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04444895 · ClinicalTrials.gov registry record · Phase 3
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
NCT04444895 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 73 participants.
The verdict
NCT04444895, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303 (NCT04206605).
Interventions
- DRUG Lanadelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04444895
The ClinicalTrials.gov registry entry for NCT04444895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanadelumab is the first listed.
NCT04444895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04444895 about?
NCT04444895 is a clinical study titled "A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor". The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303 (NCT04206605).
What is the current status of trial NCT04444895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2021-02-05. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04444895?
The interventions under investigation include: Lanadelumab (DRUG).
Who is sponsoring clinical trial NCT04444895?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.